Lilly’s Zepbound tops Novo Nordisk’s Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47 per cent more weight than those who were given ...
Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal
Eli Lilly & Co. Inc.’s stock LLY rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more ...
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head ...
Eli Lilly stock higher following surprise weight loss treatment data
Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly ...
Zepbound leads to more weight loss than Wegovy, new study finds
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
The Financial Express28m
Lilly’s Zepbound outshines Wegovy in weight loss head-to-head trial
Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...
Eli Lilly's stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.'s stock (LLY) rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk's Wegovy showed an average weight loss of 20.2% ...
Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...